Compare CSTL & WLKP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSTL | WLKP |
|---|---|---|
| Founded | 2007 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 661.7M | 652.0M |
| IPO Year | 2019 | 2014 |
| Metric | CSTL | WLKP |
|---|---|---|
| Price | $39.29 | $18.50 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $42.83 | N/A |
| AVG Volume (30 Days) | ★ 370.2K | 64.1K |
| Earning Date | 11-03-2025 | 10-30-2025 |
| Dividend Yield | N/A | ★ 10.19% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.39 |
| Revenue | $343,530,000.00 | ★ $1,133,706,000.00 |
| Revenue This Year | $1.69 | $3.88 |
| Revenue Next Year | N/A | $12.71 |
| P/E Ratio | ★ N/A | $13.26 |
| Revenue Growth | ★ 10.15 | N/A |
| 52 Week Low | $14.59 | $17.75 |
| 52 Week High | $42.18 | $25.04 |
| Indicator | CSTL | WLKP |
|---|---|---|
| Relative Strength Index (RSI) | 58.67 | 39.54 |
| Support Level | $37.76 | $19.07 |
| Resistance Level | $42.18 | $19.55 |
| Average True Range (ATR) | 1.20 | 0.41 |
| MACD | -0.35 | -0.07 |
| Stochastic Oscillator | 46.17 | 13.77 |
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
Westlake Chemical Partners LP is a part of the chemical industry in the United States. Its operations are conducted through OpCo, it acquires and develops ethylene production facilities, which convert ethane into ethylene. OpCo sells ethylene and its co-products such as propylene, crude butadiene, pyrolysis gasoline, and hydrogen to Westlake and other customers located in the United States. Its assets include three ethylene production facilities in Calvert City, Kentucky, and Lake Charles, Louisiana.